Experimental combo aims to cut deaths in severe pneumonia patients
NCT ID NCT07492875
First seen Apr 08, 2026 · Last updated Jun 13, 2026 · Updated 9 times
Summary
This study was designed to test whether adding an experimental drug (nogapendekin alfa inbakicept) and special immune cells (iNKT cells) to standard care could help critically ill adults with severe pneumonia, sepsis, or acute respiratory distress syndrome survive longer. The trial planned to enroll adults in the ICU and measure how many died within 28 days. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.